1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The Alliance Research Grant Program (including the Young Investigator Accelerator Award) is temporarily suspended as of the page visit; anticipated to reopen later in 2026 with no specific date confirmed.
Colorectal Cancer Alliance Young Investigator Accelerator Award is sponsored by Colorectal Cancer Alliance. As part of its Project Cure CRC initiative, this award supports early career investigators (within the first five years of their first independent academic faculty appointment) with original preclinical, translational, or early clinical research project ideas in colorectal cance…
Get alerted about grants like this
Save a search for “Colorectal Cancer Alliance” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Apply For a Research Grant | Colorectal Cancer Alliance Knowing your biomarker status informs the most effective treatment plan Screening & prevention: why, when, how? Take our free screening quiz for personalized recommendations Treatment: what are your options?
10 questions to ask your doctor when newly diagnosed Personalized resources are ready for you on BlueHQ Research: investments and influence to cure CRC Learn about our effort to fund expedited and novel cancer research Get involved: help us end colorectal cancer You don't have to do this alone.
Call our toll-free helpline: (877) 422-2030 The Alliance Research Grant Program (RFP) has been temporarily suspended to allow our resources to focus on establishing the adaptive clinical trial platform under Project Cure CRC . Future research funding will be dependent on available resources and alignment with this strategic priority. We anticipate reopening the RFP later in 2026; however, a specific timeline has not yet been determined.
Updates will be shared as they become available. When the program reopens, announcements will be posted. We appreciate the research community’s continued partnership and commitment to advancing colorectal cancer research.
Young Investigator Accelerator Award Supports early-career faculty with innovative ideas in CRC research, providing up to $200,000 over two years for original preclinical, translational, or early clinical projects. Senior Investigator Accelerator Award Funds transformative research to advance CRC therapies, offering up to $500,000 over two years for senior investigators proposing localized or metastatic CRC projects.
Encourages high-risk, high-reward CRC research with clear hypotheses, providing up to $200,000 over two years to establish proof-of-concept. Team Science Accelerator Award Supports collaborative, multidisciplinary CRC research teams with up to $500,000 over two years to drive curative science and innovation.
Alliance Presents Poster Sessions & Speaks at Symposium During AACR Annual Meeting The Colorectal Cancer Alliance will present three poster sessions and deliver an oral presentation at the American Association for Cancer Research Annual Meeting 2026.
Last updated Apr 15, 2026 Where breakthroughs begin: Project Cure CRC spotlight on Dr. Lisa Mielke hrough Project Cure CRC, the Alliance is fueling bold, early-stage research with the potential to transform colorectal cancer treatment. Dr. Lisa Mielke’s groundbreaking work explores how the gut’s immune system and nerve signaling influence cancer growth—opening the door to new therapeutic approaches, including repurposed existing drugs.
This is what’s possible when promising ideas get the support they need to move forward. Last updated Feb 24, 2026 Bringing biomarker testing within reach: CLEAR for CRC to empower patients from day one Biomarker testing can guide colorectal cancer treatment and improve outcomes. Learn how CLEAR for CRC is helping patients access this critical tool.
Last updated Jan 27, 2026
Based on current listing details, eligibility includes: Early career investigators (within first five years of first independent academic faculty appointment) with research projects in colorectal cancer. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Up to $200,000 over two years Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.